TrialSignal transduction and targeted therapy2025

Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study.

Dan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.